| Jennifer Janette Vanderford, APRN NP-C | |
|
800 W Boise Cir Ste 160, Broken Arrow, OK 74012-4932 | |
| (918) 994-9160 | |
| Not Available |
| Full Name | Jennifer Janette Vanderford |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 8 Years |
| Location | 800 W Boise Cir Ste 160, Broken Arrow, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356799142 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 96202 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension St John Broken Arrow | Broken arrow, OK | Hospital |
| St John Medical Center, Inc | Tulsa, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Omni Medical Group Inc | 9739080490 | 81 |
News Archive
In 2018 and 2019, the German Institute for Quality and Efficiency in Health Care already investigated whether the drug enzalutamide has an advantage in comparison with the appropriate comparator therapy, i.e. in comparison with watchful waiting while maintaining ongoing conventional androgen deprivation therapy (ADT), for adult men with high-risk non-metastatic castration-resistant prostate cancer.
Early results from the Parkinson's Progression Markers Initiative suggest that some cerebrospinal fluid biomarkers hold diagnostic and prognostic promise.
A national research team led by UC Davis Health clinicians and researchers from the University of Michigan, Nationwide Children's Hospital and Columbia University, has derived and validated a new protocol for emergency departments that can determine which infant patients with fevers, age 60 days or younger, are at low risk of significant bacterial infections.
The U.S. Food and Drug Administration (FDA) today approved Besponsa (inotuzumab ozogamicin) in the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) - a rare form of ALL.
› Verified 5 days ago
| Entity Name | St John Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336194406 PECOS PAC ID: 2567366495 Enrollment ID: O20031121000867 |
News Archive
In 2018 and 2019, the German Institute for Quality and Efficiency in Health Care already investigated whether the drug enzalutamide has an advantage in comparison with the appropriate comparator therapy, i.e. in comparison with watchful waiting while maintaining ongoing conventional androgen deprivation therapy (ADT), for adult men with high-risk non-metastatic castration-resistant prostate cancer.
Early results from the Parkinson's Progression Markers Initiative suggest that some cerebrospinal fluid biomarkers hold diagnostic and prognostic promise.
A national research team led by UC Davis Health clinicians and researchers from the University of Michigan, Nationwide Children's Hospital and Columbia University, has derived and validated a new protocol for emergency departments that can determine which infant patients with fevers, age 60 days or younger, are at low risk of significant bacterial infections.
The U.S. Food and Drug Administration (FDA) today approved Besponsa (inotuzumab ozogamicin) in the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) - a rare form of ALL.
› Verified 5 days ago
| Entity Name | Omni Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174578249 PECOS PAC ID: 9739080490 Enrollment ID: O20040115000897 |
News Archive
In 2018 and 2019, the German Institute for Quality and Efficiency in Health Care already investigated whether the drug enzalutamide has an advantage in comparison with the appropriate comparator therapy, i.e. in comparison with watchful waiting while maintaining ongoing conventional androgen deprivation therapy (ADT), for adult men with high-risk non-metastatic castration-resistant prostate cancer.
Early results from the Parkinson's Progression Markers Initiative suggest that some cerebrospinal fluid biomarkers hold diagnostic and prognostic promise.
A national research team led by UC Davis Health clinicians and researchers from the University of Michigan, Nationwide Children's Hospital and Columbia University, has derived and validated a new protocol for emergency departments that can determine which infant patients with fevers, age 60 days or younger, are at low risk of significant bacterial infections.
The U.S. Food and Drug Administration (FDA) today approved Besponsa (inotuzumab ozogamicin) in the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) - a rare form of ALL.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Janette Vanderford, APRN NP-C 800 W Boise Cir Ste 160, Broken Arrow, OK 74012-4932 Ph: (918) 994-9160 | Jennifer Janette Vanderford, APRN NP-C 800 W Boise Cir Ste 160, Broken Arrow, OK 74012-4932 Ph: (918) 994-9160 |
News Archive
In 2018 and 2019, the German Institute for Quality and Efficiency in Health Care already investigated whether the drug enzalutamide has an advantage in comparison with the appropriate comparator therapy, i.e. in comparison with watchful waiting while maintaining ongoing conventional androgen deprivation therapy (ADT), for adult men with high-risk non-metastatic castration-resistant prostate cancer.
Early results from the Parkinson's Progression Markers Initiative suggest that some cerebrospinal fluid biomarkers hold diagnostic and prognostic promise.
A national research team led by UC Davis Health clinicians and researchers from the University of Michigan, Nationwide Children's Hospital and Columbia University, has derived and validated a new protocol for emergency departments that can determine which infant patients with fevers, age 60 days or younger, are at low risk of significant bacterial infections.
The U.S. Food and Drug Administration (FDA) today approved Besponsa (inotuzumab ozogamicin) in the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) - a rare form of ALL.
› Verified 5 days ago
Carmen Kay Oakes, ARNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3300 S Aspen Ave Ste C, Broken Arrow, OK 74012 Phone: 918-237-9627 | |
Makeda Gant, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1129 S Aspen Ave, Broken Arrow, OK 74012 Phone: 918-764-9300 Fax: 918-764-9275 | |
Mrs. Kristi Gene Sager, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4623 W Kenosha St, Broken Arrow, OK 74012 Phone: 918-693-0834 | |
Ms. Kyndal Renee' Stevens, APRN-CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2617 S Elm Pl, Broken Arrow, OK 74012 Phone: 918-455-0414 | |
Ms. Mary Constance Starr, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 818 S Aspen Ave, Broken Arrow, OK 74012 Phone: 918-258-2952 | |
Ms. Jamie Larie Kitchens, DNP, APRN, CNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2617 S Elm Pl, Broken Arrow, OK 74012 Phone: 918-455-4541 Fax: 918-455-0414 | |
Mrs. Christina Lou Martin, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1551 N 9th St, Broken Arrow, OK 74012 Phone: 918-355-7900 Fax: 918-355-7929 |